Pharmaceuticals MD $500K+ Reviewed

Generally Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and industry partners

US Army

medical countermeasures monoclonal antibodies vaccines small molecule drugs $500K+

Posted Oct 18, 2024

Due Oct 18, 2028

Description

The US Army's GUIDE program solicits participation from U.S. interagency, academic, and industry partners to collaborate on an integrated computational and experimental platform that accelerates medical countermeasure development, including biological products like monoclonal antibodies and vaccines, as well as small molecule drugs, by optimizing attributes such as safety, efficacy, manufacturability, and pharmacokinetics. This initiative, managed under a Participant Basic Agreement (PBA) by the Joint Project Lead for Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies (JPL-CBRND-EB), targets entities with demonstrated expertise in medical countermeasure innovation for rapid warfighter protection against dynamic threats. Qualified bidders must submit technical relevancy demonstrations via email to the designated contact.

A strong match for healthcare vendors

Curated for medical & healthcare suppliers

Why we classified this as medical

This bid focuses on accelerating development of medical countermeasures like vaccines, monoclonal antibodies, and small molecule drugs using AI and computational platforms for warfighter protection. It directly aligns with pharmaceuticals and drug/vaccine discovery, highly relevant to medical/healthcare vendors in biotech and pharma sectors.

View Original Source

Save for Later

Send to Pipeline

Closing date unconfirmed

This bid lists a closing date of Oct 18, 2028, which is more than a year out — almost certainly a data error from the source. Treat the deadline as unknown.

Please confirm the actual deadline on the original source before you rely on it.

Check the source